Treatment of relapsing-remittent multiple sclerosis with recombinant human interferon-alfa-2a: design of a randomised, placebo-controlled, double blind trial in Norway.
A multicentre, randomised, double-blind, placebo controlled study to evaluate the efficacy and safety of 4.5 and 9.0 MIU recombinant human interferon alfa-2a (Roferon-A) given thrice weekly in patients with relapsing-remittent multiple sclerosis is described. The patients are treated for 6 months followed by a 6 months drug-free period. The primary objective is to determine new disease activity analysed by monthly MRI with gadodiamide (GdDTPA-BMA, Omniscan). The study is conducted at eight centers in Norway and is completed in January 1996.
Nyland
H
H
Department of Neurology, University of Bergen, Norway.
Myhr
K M
KM
Lillås
F
F
Smievoll
A I
AI
Riise
T
T
Nortvedt
M
M
Nilsen
R
R
D003287:Contrast Media; D004311:Double-Blind Method; D019786:Gadolinium DTPA; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use*; D008279:Magnetic Resonance Imaging / Q000379:methods*; D009103:Multiple Sclerosis / Q000175:diagnosis / Q000188:drug therapy*; D009664:Norway; D011994:Recombinant Proteins; D012008:Recurrence; D012074:Remission Induction / Q000379:methods
D003287:Contrast Media; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; C064925:gadodiamide; D019786:Gadolinium DTPA